1527P Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification

Jiajia Yuan(Peking University), Lele Song(Chinese PLA General Hospital), Hongli Xu(Hubei Cancer Hospital), Cuicui Lyu(Tianjin First Center Hospital), Lin Shen(Peking University), Yuxin Li(Army Medical University), Xiaoxian Zhang(North University of China), Jing Wei(Earth System Science Interdisciplinary Center), Tianshu Liu(Sun Yat-sen University), J. H. Yang(Fujian Provincial Cancer Hospital), Haiping Jiang, J. Gong(Peking University), Yifang Wang(Lawrence Berkeley National Laboratory), Yanhong Deng(Sun Yat-sen University)
Annals of Oncology
October 1, 2023
10.1016/j.annonc.2023.09.1439
Cited by 7

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Improved 1 km resolution PM <sub>2.5</sub> estimates across China using enhanced space–time extremely randomized trees
|Atmospheric chemistry and physics|2020|650